Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GS-3583 + docetaxel
- Development stage
- Discontinued
- Lead developer
- Gilead Sciences
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
GS-3583 + docetaxel is an investigational combination regimen consisting of **GS-3583**, a novel FLT3 agonist Fc fusion protein, and **docetaxel**, a well-established taxane chemotherapy. GS-3583 acts by agonizing Fms-like tyrosine kinase 3 (FLT3) on myeloid and lymphoid progenitor cells, resulting in the expansion of conventional dendritic cells (cDCs), including cDC1 and cDC2, in the periphery and potentially in the tumor microenvironment. This dendritic cell mobilization is intended to enhance T-cell mediated antitumor immunity in patients with solid tumors[1][2][3][4][5][8]. Docetaxel disrupts microtubule dynamics by stabilizing GDP-bound tubulin in the microtubule, inhibiting cell division and inducing apoptosis in rapidly dividing cells. The combination is under clinical investigation, in particular for advanced solid tumors and non-small cell lung cancer (NSCLC), where GS-3583 is given intravenously alongside docetaxel.
- Other names
- GS-3583 + docetaxel
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on GS-3583 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GS-3583 + docetaxel.